Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients.
Through the partnership Axxam’s highly curated chemical diversity library, comprised of 325,000 compounds, will be available for high-throughput screening using Momentum’s mass spectrometry-based functional and binding assay platforms. Primary hits may
be progressed in hit-to-lead projects and addional downstream experiments including testing in cellbased assays.
Axxam is a leader in providing early drug discovery services, offering a wide range of applications in addition to an extensive chemical diversity library. The Axxam library was built using decades of broad screening experience and significant input from medicinal and computaonal chemists. The library is composed of small molecules carefully selected for quality and structural diversity.
Momentum Biotechnologies is a bioanalytical contract research organization (CRO) specializing in early drug discovery and offers mass spectrometry-based high-throughput functional and binding assays. Founded by the team that originally commercialized the RapidFire™ high-throughput mass spectrometry platform, the company has decades of screening and hit characterizaon experience.
“We are thrilled to enter this collaboration with Axxam” said Can Ozbal, CEO of Momentum. “Our clients will now have the opon to access additional chemical matter for their drug discovery programs further enhancing our affinity selection mass spectrometry and functional assay services”.
Axxam CEO Stefan Lohmer added “with this collaboration Axxam clients will now have access to mass spectrometry-based HTS and hit-to-lead technologies expanding upon the wide range of services existing within the Axxam portfolio”.
For more information, please visit www.axxam.com.